Breast health

Benign Biopsy Results: A Pathology Glossary

Save

A benign breast biopsy result means no cancer was found in the tissue sample. Pathology terms like fibrocystic change, fibroadenoma, sclerosing adenosis, and usual ductal hyperplasia describe common non-cancerous findings. Most breast biopsies return a benign result, and the report guides whether routine follow-up or added imaging is suggested.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

What does a benign result actually mean?

Benign means the cells under the microscope are not cancer. A pathologist examines the sample removed during your biopsy and describes what the tissue is made of, not only what it is not.

According to the American College of Obstetricians and Gynecologists, most breast findings that lead to a biopsy prove benign 1; in everyday terms, roughly 8 in 10 biopsies return a non-cancerous result. A benign result does not raise your future risk in most cases. The report may still note a follow-up mammogram or a short-interval recheck, which confirms stability over time rather than signaling concern.

Which benign terms show up most often?

Fibrocystic change is the most common benign finding, describing the normal lumpiness, cysts, and fibrous tissue that shift with your cycle and often ease after menopause as estrogen falls. Fibroadenoma, a smooth non-cancerous growth, is especially common from adolescence through the thirties.

Sclerosing adenosis and usual ductal hyperplasia describe extra but orderly cell growth in the ducts or lobules, and both sit at the low end of the risk spectrum. Dense breast tissue, present in nearly half of women at about 40 to 50 percent, can make findings harder to read 2. A radiologist confirms the pathology matches what the imaging predicted.

Are all benign findings truly low-risk?

Most benign results carry no added risk, but a few sit in a gray zone that pathologists flag. Atypical ductal hyperplasia and atypical lobular hyperplasia are benign yet mark a modestly higher future risk, so they often prompt closer surveillance.

A radial scar or a papilloma may occasionally be watched or removed to be certain. Fewer than 1 in 10 benign results carry this atypical label. According to national cancer guidance, family history and inherited factors also shape how a result is interpreted 3. Knowing which category applies helps you and your clinician choose between routine screening by age and a shorter recheck.

How should you read the full pathology report?

A pathology report follows a predictable structure once you know the parts. The top lists your identifying details and the specimen site, while the final diagnosis line carries the key result in plain pathology terms.

A phrase such as benign or no malignancy identified is the reassuring headline, and comments about margins, calcifications, or correlation with imaging round out the picture. If a breast lump prompted the biopsy, the report explains what that lump was. Most reports are ready within 5 to 7 days, and keeping a copy gives you a useful baseline if imaging changes later.

When benign breast biopsy results need another look

A benign result is reassuring, yet a few situations still deserve a clinician's eyes. A breast surgeon, radiologist, or your primary clinician can confirm the pathology fits the imaging, explain any atypical wording, and set the right follow-up interval.

Bring your report, your images if you have them, and any family history of breast or ovarian cancer to that visit. According to well-woman guidance, most people with a benign result simply return to age-appropriate screening 4. Gale can help you prepare questions before you go.

Common questions

No. A benign result means no cancer was found in that sample, but routine screening continues on the schedule your clinician recommends for your age and risk. A benign biopsy is a helpful baseline, not a reason to stop future imaging.

Benign means non-cancerous. Atypical findings, such as atypical ductal hyperplasia, are also non-cancerous but show cells that look slightly unusual and are linked to a modestly higher future risk. Atypical results often lead to closer monitoring or a discussion about added steps with a specialist.

Generally no. Fibrocystic change describes normal lumpiness, cysts, and fibrous tissue that many people have, and it is not cancer or a strong risk factor. It can make breasts feel tender or lumpy, especially before a period, and it often eases after menopause.

For most straightforward benign results it is not necessary, but a second read can be reasonable if the wording is unclear, the pathology does not match the imaging, or you have a strong family history. Your clinician can arrange a review of the slides if there is any question.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When a benign result still needs review

  • —A pathology result that does not match what your imaging showed is a reason to seek repeat evaluation.
  • —Wording such as atypical or cannot exclude malignancy on your report is a reason to ask for a breast specialist's review.
  • —A new or growing lump after a benign result is a reason to contact your clinician.
  • —A strong family history of breast or ovarian cancer is a reason to ask about genetic counseling.

This article is general health education, not a diagnosis. A benign result and its follow-up are best interpreted with a radiologist, breast surgeon, or your primary clinician who can see your full imaging and history.

References

  1. 1.American College of Obstetricians and Gynecologists (2017). Practice Bulletin Number 179: Breast Cancer Risk Assessment and Screening in Average-Risk Women. Obstetrics & Gynecology. doi:10.1097/AOG.0000000000002158 ✓ACOG breast-screening bulletin supporting that most breast findings prompting a biopsy are benign and that imaging-pathology correlation frames how a benign result is read.
  2. 2.National Cancer Institute (PDQ Screening and Prevention Editorial Board) (2025). Breast Cancer Screening. National Cancer Institute (NCI), NIH. link ✓NCI patient screening summary supporting breast-density prevalence (roughly 40-50% of women) and that most abnormal mammograms and biopsies are not cancer.
  3. 3.National Cancer Institute (2024). BRCA Gene Changes: Cancer Risk and Genetic Testing Fact Sheet. National Cancer Institute (NCI), NIH. link ✓NCI fact sheet supporting how family history and inherited BRCA-related risk shape interpretation and follow-up of benign breast findings.
  4. 4.American College of Obstetricians and Gynecologists (2018). ACOG Committee Opinion No. 755: Well-Woman Visit. Obstetrics & Gynecology. doi:10.1097/AOG.0000000000002897 ✓ACOG well-woman guidance supporting a return to age-appropriate breast screening and clinician follow-up after a benign result.

4 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library